Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT04897009

Active, not recruiting

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer (ENHANCE)

Invasive Breast Carcinoma
NCT04059484

Terminated

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Breast Cancer Metastatic
NCT07008963

Completed

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Metastatic Breast Cancer
NCT05296317

Completed

Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (EMEG-ECDD)

Localized Breast Cancer
NCT06216574

Active, not recruiting

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial (SHINE)

Breast Cancer Female
NCT03063073

Completed

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block (pec's)

Breast Cancer Female
NCT03377036

Active, not recruiting

Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography (TOSYMA)

Breast Cancer Screening
NCT02738866

Active, not recruiting

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Metastatic Breast Cancer
NCT06660030

Terminated

Factors Influencing Tamoxifen Adherence in Women With Breast Cancer Receiving Tamoxifen in Botswana. (TAM)

Breast Cancer Female
NCT06612203

Active, not recruiting

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (WIN-B)

Advanced Breast Cancer
NCT06408038

Completed

Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer (DP METABREAST)

Metastatic Breast Cancer
NCT03079011

Completed

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (PADA-1)

Metastatic Breast Cancer
NCT03147287

Active, not recruiting

Palbociclib After CDK and Endocrine Therapy (PACE)

Metastatic Breast Cancer
NCT04265547

Completed

Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition

Breast Cancer Risk
NCT04815083

Terminated

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Breast Cancer | Breast Neoplasm Female
NCT02022202

Completed

Breast Cancer Genome Guided Therapy Study (BEAUTY) (BEAUTY)

Invasive Breast Cancer
NCT01531036

Completed

3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy

Malignant Breast Tumours
NCT06059300

Active, not recruiting

Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program (STREAM)

Breast Cancer Screening
NCT07059897

Completed

Effectiveness of a Video and Mobile App in Breast Cancer Screening Awareness (Application)

Breast Cancer Awareness
NCT05132101

Completed

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Metastatic Breast Cancer
NCT01526369

Completed

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (TH V THL)

Metastatic Breast Cancer
NCT06214793

Suspended

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Breast Cancer | Metastatic Breast Cancer
NCT05207709

Active, not recruiting

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA)

Metastatic Breast Cancer
NCT02423603

Completed

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT)

Metastatic Breast Cancer
NCT04432454

Completed

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)

Metastatic Breast Cancer
NCT00248287

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer
NCT06371508

Completed

Breast Cancer and Breast Self-examination Education

Breast Cancer | Breast Self-Examination
NCT03238196

Completed

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Metastatic Breast Cancer
NCT03205761

Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast)

Advanced Breast Cancer
NCT06161181

Completed

Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients

Metastatic Breast Cancer
NCT06619704

Completed

Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy

Metastatic Breast Cancer
NCT03355157

Completed

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)

Metastatic Breast Cancer
NCT02802553

Active, not recruiting

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions

Invasive Breast Cancer
NCT04708860

Completed

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Breast Cancer | Metastatic Breast Cancer
NCT04857619

Completed

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Metastatic Breast Cancer
NCT00358098

Terminated

Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Metastatic Breast Cancer
NCT05361655

Completed

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Metastatic Breast Cancer
NCT02344472

Active, not recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Metastatic Breast Cancer
NCT05203458

Completed

Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)

Breast Cancer, HER2
NCT03915548

Completed

Optimizing Functional Recovery of Breast Cancer Survivors

Breast Cancer Female
NCT06376578

Completed

Exercise Interventions for Improving Health in Breast Cancer Survivors

Breast Cancer Female
NCT01942135

Completed

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Metastatic Breast Cancer
NCT05850637

Completed

Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer

Breast Cancer Female
NCT05082740

Completed

FH-Risk 2.0: Updating Breast Cancer Risk Estimates

Breast Cancer Risk
NCT05245162

Withdrawn

Fertility Changes Due to Cancer: an Investigation of Meaning, Psychological Distress, and Psychologi

Breast Cancer Female
NCT03321981

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic
NCT03595592

Active, not recruiting

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

Invasive Breast Cancer
NCT04240106

Completed

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (LUZERN)

Breast Cancer | Breast Cancer Metastatic
NCT03737266

Completed

Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy

Breast Cancer Surgery
NCT01956552

Terminated

Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)

Metastatic Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations